Published April 1, 2025
| Version v1
Journal article
Open
Design, Formulation and Evaluation of Enzalutamide Nano Sponge Using BOX-Behnken Design for Management of Prostate Cancer
- 1. *1Research Scholar, Faculty of Pharmaceutical Sciences, Motherhood University, Dehradun Road, Karoundi village, Bhagwanpur post, Roorkee Tehsil, Haridwar Distt., Uttarakhand, India-247661. 2Professor, Faculty of Pharmaceutical Sciences, Motherhood University, Dehradun Road, Karoundi village, Bhagwanpur post, Roorkee Tehsil, Haridwar Distt., Uttarakhand, India-247661. 3Professor, Beside L.M.D Police Station, Ramakrishna Colony, Thimmapur, Karimnagar, Telangana State, India-505527
Contributors
Researcher:
- 1. *1Research Scholar, Faculty of Pharmaceutical Sciences, Motherhood University, Dehradun Road, Karoundi village, Bhagwanpur post, Roorkee Tehsil, Haridwar Distt., Uttarakhand, India-247661.
Description
Enzalutamide (EZL) is a potent androgen receptor inhibitor widely used for the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, its poor aqueous solubility and limited oral bioavailability pose significant challenges in achieving optimal therapeutic outcomes. This study aimed to design and evaluate a sustained-release nano sponge (NS) delivery system for EZL using β-cyclodextrin (β-CD) as the polymer matrix. Nano sponges were prepared by the solvent evaporation method using dimethyl carbonate as a cross-linker and optimized through a Box-Behnken Design (BBD) under a Quality by Design (QbD) framework. The effects of polymer concentration, cross-linker amount, and reaction time were assessed on critical quality attributes such as particle size, entrapment efficiency, polydispersity index (PDI), and zeta potential. The optimized formulation exhibited a particle size of 168.9 nm, entrapment efficiency of 85.47%, and zeta potential of −26.75 mV, indicating good colloidal stability. Characterization through FTIR, DSC, and XRD confirmed successful drug encapsulation and reduced crystallinity. In vitro drug release studies demonstrated a biphasic release profile with sustained drug release up to 88.5% over 12 hours. Furthermore, pharmacokinetic evaluation in rats revealed a 2.5-fold increase in bioavailability, extended half-life, and improved mean residence time compared to free EZL. The findings suggest that β-CD-based nano sponges are a promising nanocarrier system for enhancing the solubility, stability, and therapeutic performance of EZL. This approach may improve patient compliance and treatment efficacy in prostate cancer therapy.
Keywords
Enzalutamide; Box-Behnken Design; prostate cancer; β-cyclodextrin; Pharmacokinetic; Nano sponges.
Files
53-67-Srinivas-I-ijpbs.pdf
Files
(999.1 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:6e31099e816722d6f3efc696a4f9da2b
|
999.1 kB | Preview Download |
Additional details
Dates
- Available
-
2025-04-01Volume 15 issue 1 2025
References
- 1. Okaiyeto, K., & Oguntibeju, O. (2021). African herbal medicines: Adverse effects and cytotoxic potentials with different therapeutic applications. International Journal of Environmental Research and Public Health, 18(5988). https://doi.org/10.3390/ijerph18115988 2. Kuruppu, A. I., Paranagama, P., & Goonasekara, C. L. (2019). Medicinal plants commonly used against cancer in traditional medicine formulae in Sri Lanka. Saudi Pharmaceutical Journal, 27, 565–573. Matowa, P. R., Gundidza, M., Gwanzura, L., & Nhachi, C. F. B. (2020). A survey of ethnomedicinal plants used to treat cancer by traditional medicine practitioners in Zimbabwe. BMC Complementary Medicine and Therapies, 20, 278. 3. Ahmadibeni, Y., Karim, K., & Boadi, W. (2017). Abstract 2180: Triphenylmethanol conjugates of leuprorelin as anti-cancer prodrugs. Cancer Research, 77(13 Supplement), 2180. Hashemi, S. R., & Davoodi, H. (2011). Herbal plants and their derivatives as growth and health promoters in animal nutrition. Veterinary Research Communications, 35, 169–180. 4. Kumar, G. P., & Khanum, F. (2012). Neuroprotective potential of phytochemicals. Pharmacognosy Reviews, 6, 81–90. 5. Alara, J. A., & Alara, O. R. (2019). Ethno-medicinal potentials and phytochemical properties of Aloe vera: A review. Journal of Chemical Engineering, Industrial and Biotechnological Research, 5, 57–73. 6. Crocetto, F., Di Zazzo, E., Buonerba, C., Aveta, A., Pandolfo, S. D., Barone, B., et al. (2021). Kaempferol, myricetin and fisetin in prostate and bladder cancer: A systematic review of the literature. Nutrients, 13(3750). 7. Iqbal, J., Abbasi, B. H., Mahmood, T., Kanwal, S., Ali, B., Shah, S. A., & Khalil, A. T. (2017). Plant-derived anticancer agents: A green anticancer approach. Asian Pacific Journal of Tropical Biomedicine, 7, 1129–1150. 8. Gori, J. L., Hsu, P., Maeder, M. L., Shen, S., Welstead, G. G., & Bumcrot, D. (2015). Delivery and specificity of CRISPR/Cas9 genome editing technologies for human gene therapy. Human Gene Therapy, 26, 443–451. 9. Chen, Y. H., Keiser, M. S., & Davidson, B. L. (2018). Viral vectors for gene transfer. Current Protocols in Mouse Biology, 8, e58. 10. Jan, R., & Chaudhry, G.-E. (2019). Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. Advanced Pharmaceutical Bulletin, 9, 205–218. 11. Verma, A. K., Mandal, S., Tiwari, A., Monachesi, C., Catassi, G. N., Srivastava, A., et al. (2021). Current status and perspectives on the application of CRISPR/Cas9 gene-editing system to develop a low-gluten, non-transgenic wheat variety. Foods, 10(2351). 12. Singh, V., Khurana, A., Navik, U., Allawadhi, P., Bharani, K. K., & Weiskirchen, R. (2022). Apoptosis and pharmacological therapies for targeting thereof for cancer therapeutics. Sci, 4(15). 13. Sharifi, N., Salmaninejad, A., Ferdosi, S., Bajestani, A. N., Khaleghiyan, M., Estiar, M. A., et al. (2016). HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method. Oncology Letters, 12, 4651–4658. 14. Rossini, A., Giussani, M., Ripamonti, F., Aiello, P., Regondi, V., Balsari, A., et al. (2020). Combined targeting of EGFR and HER2 against prostate cancer stem cells. Cancer Biology & Therapy, 21, 463–475. 15. Jiang, F., Liang, Y., Wei, W., Zou, C., Chen, G., Liu, Z., et al. (2020). Functional classification of prostate cancer-associated miRNAs through CRISPR/Cas9-mediated gene knockout. Molecular Medicine Reports, 22, 3777–3784. 16. Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., et al. (2020). Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Frontiers in Molecular Biosciences, 7, 193. 17. Desai, N., Momin, M., Khan, T., Gharat, S., Ningthoujam, R. S., & Omri, A. (2021). Metallic nanoparticles as drug delivery system for the treatment of cancer. Expert Opinion on Drug Delivery, 18, 1261–1290. 18. Mount Sinai School of Medicine. (2019, August 27). Gold nanoparticles shown to be safe and effective treatment for prostate cancer. ScienceDaily. https://www.sciencedaily.com/releases/2019/08/190827123513.htm 19. Sechi, M., Sanna, V., & Pala, N. (2014). Targeted therapy using nanotechnology: Focus on cancer. International Journal of Nanomedicine, 9, 467–483. 20. Gregg, J. R., & Thompson, T. C. (2021). Considering the potential for gene-based therapy in prostate cancer. Nature Reviews Urology, 18, 170–184. 21. Balon, K., Sheriff, A., Jacków, J., & Łaczmański, Ł. (2022). Targeting cancer with CRISPR/Cas9-based therapy. International Journal of Molecular Sciences, 23, 573. 22. Amarachinta, P. R., Sharma, G., Samed, N., Chettupalli, A. K., Alle, M., & Kim, J. C. (2021). Central composite design for the development of carvedilol-loaded transdermal ethosomal hydrogel for extended and enhanced anti-hypertensive effect. Journal of Nanobiotechnology, 19, 1–5. 23. Chettupalli, A. K., Ananthula, M., Amarachinta, P. R., Bakshi, V., & Yata, V. K. (2021). Design, formulation, in-vitro and ex-vivo evaluation of atazanavir loaded cubosomal gel. Biointerface Research in Applied Chemistry, 11(4), 12037–12054. 24. Unnisa, A., Chettupalli, A. K., Al Hagbani, T., Khalid, M., Jandrajupalli, S. B., Chandolu, S., & Hussain, T. (2022). Development of dapagliflozin solid lipid nanoparticles as a novel carrier for oral delivery: Statistical design, optimization, in-vitro and in-vivo characterization, and evaluation. Pharmaceuticals, 15(5), 568. 25. Unnisa, A., Chettupalli, A. K., Hussain, T., & Kamal, M. A. (2022). Recent advances in epidermal growth factor receptor inhibitors (EGFRIs) and their role in the treatment of cancer: A review. Anti-Cancer Agents in Medicinal Chemistry, 22(20), 3370–3381. 26. Unnisa, A., Chettupalli, A. K., Alazragi, R. S., Alelwani, W., Bannunah, A. M., Barnawi, J., Amarachinta, P. R., Jandrajupalli, S. B., Elamine, B. A., Mohamed, O. A., & Hussain, T. (2023). Nanostructured lipid carriers to enhance the bioavailability and solubility of ranolazine: Statistical optimization and pharmacological evaluations. Pharmaceuticals, 16(8), 1151. 27. Chettupalli, A. K., Rao, P. A., Kuchukuntla, M., & Bakshi, V. (2020). Development and optimization of aripiprazole ODT by using Box–Behnken design. Research Journal of Pharmacy and Technology, 13(12), 6195–6201. 28. Avula, P. R., Chettupalli, A. K., Chauhan, V., & Jadi, R. K. (2023). Design, formulation, in-vitro and in-vivo pharmacokinetic evaluation of nicardipine-nanostructured lipid carrier for transdermal drug delivery system. Materials Today: Proceedings. Advance online publication. https://doi.org/10.1016/j.matpr.2023.07.012. 29. Prasad, R. R., Kumar, J. R., Vasudha, B. A., & Kumar, C. A. (2018). Formulation development and evaluation of allopurinol solid dispersions by solvent evaporation technique. International Journal of Applied Pharmaceutics, 10(4), 168–171. 30. Chettupalli, A. K., Amara, R. R., Amarachinta, P. R., Manda, R. M., Garige, B. S., & Yata, V. K. (2021). Formulation and evaluation of polyherbal liqui-solid compact for its anti-inflammatory effect. Biointerface Research in Applied Chemistry, 12, 3883–3899. 31. Chettupalli, A. K., Ajmera, S., Amarachinta, P. R., Manda, R. M., & Jadi, R. K. (2023). Quality by design approach for preparation, characterization, and statistical optimization of naproxen sodium-loaded ethosomes via transdermal route. Current Bioactive Compounds, 19(10), 79–98. 32. Unnisa, A., & Chettupalli, A. K. (2022). Promising role of phytochemicals in the prevention and treatment of cancer. Anti-Cancer Agents in Medicinal Chemistry, 22(20), 3382–3400. 33. Chettupalli, A. K., Ajmera, S., Kuchukuntla, M., Palanivel, V., & Katta, S. (2024). Design formulation of nanospanlastic novel carriers as a promising approach to enhanced bioavailability in intranasal drug delivery for sinusitis: Statistical optimization and in vitro and in vivo characterization. Current Nanomedicine, 14(3), 266–288. 34. Xu, H., Kita, Y., Bang, U., Gee, P., & Hotta, A. (2021). Optimized electroporation of CRISPR-Cas9/gRNA ribonucleoprotein complex for selection-free homologous recombination in human pluripotent stem cells. STAR Protocols, 2, 100965. 35. Rosenblum, D., Gutkin, A., Kedmi, R., Ramishetti, S., Veiga, N., Jacobi, A. M., et al. (2020). CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Science Advances, 6(47), eabc9450. 36. Ye, R., Pi, M., Cox, J. V., Nishimoto, S. K., & Quarles, L. D. (2017). CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model. Journal of Experimental & Clinical Cancer Research, 36, 90. 37. Tsujino, T., Komura, K., Inamoto, T., & Azuma, H. (2021). CRISPR screen contributes to novel target discovery in prostate cancer. International Journal of Molecular Sciences, 22, 12777. 38. Friedman, A. D., Claypool, S. E., & Liu, R. (2013). The smart targeting of nanoparticles. Current Pharmaceutical Design, 19, 6315–6329. 39. Li, K., Zhan, W., Chen, Y., Jha, R. K., & Chen, X. (2019). Docetaxel and doxorubicin co-delivery by nanocarriers for synergistic treatment of prostate cancer. Frontiers in Pharmacology, 10, 1436. 40. Autio, K. A., Dreicer, R., Anderson, J., Garcia, J. A., Alva, A., Hart, L. L., et al. (2018). Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: A phase 2 clinical trial. JAMA Oncology, 4(9), 1344–1351. 41. Johannsen, M., Thiesen, B., Wust, P., & Jordan, A. (2010). Magnetic nanoparticle hyperthermia for prostate cancer. International Journal of Hyperthermia, 26(8), 790–795. 42. He, M.-H., Chen, L., Zheng, T., Tu, Y., He, Q., Fu, H.-L., et al. (2018). Potential applications of nanotechnology in urological cancer. Frontiers in Pharmacology, 9, 745. 43. Yap, T. A., Smith, A. D., Ferraldeschi, R., Al-Lazikani, B., Workman, P., & De Bono, J. S. (2016). Drug discovery in advanced prostate cancer: Translating biology into therapy. Nature Reviews Drug Discovery, 15, 699–718. 44. Tüfekci, K. U., Öner, M. G., Meuwissen, R. L. J., & Genç, Ş. (2013). The role of microRNAs in human diseases. In miRNomics: MicroRNA Biology and Computational Analysis (pp. 33–50). Humana Press. 45. Johnson, T. M. (2017). Perspective on precision medicine in oncology. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 37(8), 988–989. 46. Aiassa, V., Garnero, C., Longhi, M. R., & Zoppi, A. (2021). Cyclodextrin multicomponent complexes: Pharmaceutical applications. Pharmaceutics, 13(7), 1099. 47. Mane, P. T., Wakure, B. S., & Wakte, P. S. (2021). Cyclodextrin-based nanosponges: A multidimensional drug delivery system and its biomedical applications. Current Drug Delivery, 18(10), 1467–1493. 48. Sherje, A. P., Dravyakar, B. R., Kadam, D., & Jadhav, M. (2017). Cyclodextrin-based nanosponges: A critical review. Carbohydrate Polymers, 173, 37–49. 49. Iravani, S., & Varma, R. S. (2022). Nanosponges for water treatment: Progress and challenges. Applied Sciences, 12(9), 4182. 50. Lembo, V., Folini, D., Wild, M., & Lionello, P. (2019). Inter-hemispheric differences in energy budgets and cross-equatorial transport anomalies during the 20th century. Climate Dynamics, 53(1), 115–135. 51. Almutairy, B. K., Alshetaili, A., Alali, A. S., Ahmed, M. M., Anwer, M. K., & Aboudzadeh, M. A. (2021). Design of olmesartan medoxomil-loaded NSs for hypertension and lung cancer treatments. Polymers, 13(14), 2272.